CV Sciences, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
CVSIStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)
(in thousands)
| Common Stock · AdditionalPaid-In · Accumulated · Accumulated Other Comprehensive | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Income (Loss) | Total | |
| Balance at December 31, 2024 | 184,264 | $18 | $88,773 | $(86,981) | $(15) | $1,795 |
| Vesting of common stock for services | — | — | 60 | — | — | 60 |
| Stock-based compensation | — | — | 118 | — | — | 118 |
| Foreign currency translation adjustment | — | — | — | — | 28 | 28 |
| Net loss | — | — | — | (109) | — | (109) |
| Balance at March 31, 2025 | 184,264 | $18 | $88,951 | $(87,090) | $13 | $1,892 |
| Common Stock · AdditionalPaid-In · Accumulated · Accumulated Other Comprehensive | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Income (Loss) | Total | |
| Balance at December 31, 2023 | 161,678 | $16 | $87,464 | $(84,587) | $10 | $2,903 |
| Issuance of common stock for services | 1,550 | — | 62 | — | — | 62 |
| Stock-based compensation | — | — | 30 | — | — | 30 |
| Foreign currency translation adjustment | — | — | — | — | (5) | (5) |
| Net loss | — | — | — | (628) | — | (628) |
| Balance at March 31, 2024 | 163,228 | $16 | $87,556 | $(85,215) | $5 | $2,362 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.